Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).

标题：随机对照试验：标准化疗单药对比联合阿替利珠单抗（Atezolizumab）作为Ⅲ期DNA错配修复缺陷（dMMR）结肠癌患者的辅助治疗

讲者：Frank A. Sinicrope, MD | Mayo Clinic Rochester

NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.

标题：Ⅲ期随机试验评估复发高风险头颈部鳞状细胞癌术后患者在放化疗基础上加用纳武利尤单抗（Nivolumab）辅助治疗的疗效

讲者：Jean Bourhis Sr, MD, PhD | CHUV, Bâtiment Hospitalier

Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV).

标题：Rusfertide治疗真性红细胞增多症（PV）的Ⅲ期双盲、安慰剂对照试验

讲者：Andrew Tucker Kuykendall, MD | Moffitt Cancer Center

Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.Camizestrant

标题：联合CDK4/6抑制剂（CDK4/6i）用于HR+/HER2–晚期乳腺癌（ABC）患者一线内分泌治疗期间新发ESR1突变且疾病进展前的治疗——基于ctDNA指导的Ⅲ期双盲临床试验

讲者：Nicholas C. Turner, MD, PhD | Royal Marsden Hospital

Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).

标题：MATTERHORN研究无事件生存期（EFS）分析：Ⅲ期随机试验评估度伐利尤单抗（Durvalumab）联合5-氟尿嘧啶、亚叶酸、奥沙利铂和多西他赛化疗（FLOT方案）在可切除胃/胃食管结合部癌（GC/GEJC）中的疗效

讲者：Yelena Y. Janjigian, MD | Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center